Chemistry:TGBA01AD

TGBA01AD
Clinical data
Other names	FKB01MD
Routes of; administration	By mouth
Pharmacokinetic data
Bioavailability	17%
Elimination half-life	4 hours
Chemical and physical data
3D model (JSmol)	Interactive image;
	SMILES OCC1OC(C(O)C1O)C2(O)NC=CC(=O)N2;
	InChI InChI=1S/C9H14N2O6/c12-3-4-6(14)7(15)8(17-4)9(16)10-2-1-5(13)11-9/h1-2,4,6-8,10,12,14-16H,3H2,(H,11,13); Key:QJTQVQQHNGHIKY-UHFFFAOYSA-N;

Short description: Investigational antidepressant drug

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT_1A and 5-HT_1D receptor agonist, and 5-HT₂ receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.^[2]^[1]^[3] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.^[4]

References

↑ ^1.0 ^1.1 ^1.2 "FKB01MD". Fabre-Kramer. http://www.fabrekramer.com/?page_id=66.
↑ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595.
↑ "Serotonin receptors in depression and anxiety: Insights from animal studies". Life Sciences 210: 106–124. October 2018. doi:10.1016/j.lfs.2018.08.050. PMID 30144453.
↑ "TGBA01AD". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800029513.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/TGBA01AD. Read more

Clinical data
Other names	FKB01MD
Routes of administration	By mouth
Pharmacokinetic data
Bioavailability	17%^[1]
Elimination half-life	4 hours^[1]
Chemical and physical data
3D model (JSmol)	Interactive image
SMILES OCC1OC(C(O)C1O)C2(O)NC=CC(=O)N2
InChI InChI=1S/C9H14N2O6/c12-3-4-6(14)7(15)8(17-4)9(16)10-2-1-5(13)11-9/h1-2,4,6-8,10,12,14-16H,3H2,(H,11,13) Key:QJTQVQQHNGHIKY-UHFFFAOYSA-N